Cangene
As of the edition of 20 October 2026, Cangene runs 2 drugs, 2 of them marketed.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 2 |
| Total | 2 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Somatropin | Ended 2003 (orphan exclusivity) | 4 |
| Varicella-zoster immune globulin | Ended 2024 (computed from the first US licence) | 0 |
A route B row is one company at one target.
Where its trials are
- Infections: 1 trials led